Infectious Diseases (COVID-19 Access Restrictions and Clearance) (Amendment No. 4) Regulations 2022

No. S 91

Infectious Diseases Act 1976

Infectious Diseases
(COVID-19 Access Restrictions and Clearance)
(Amendment No. 4) Regulations 2022

In exercise of the powers conferred by section 73(1) of the Infectious Diseases Act 1976, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Infectious Diseases (COVID‑19 Access Restrictions and Clearance) (Amendment No. 4) Regulations 2022 and come into operation on 14 February 2022.

Amendment of regulation 2

2. Regulation 2(1) of the Infectious Diseases (COVID‑19 Access Restrictions and Clearance) Regulations 2021 (G.N. No. S 273/2021) (called in these Regulations the principal Regulations) is amended —

(a)

by deleting the words “, (5) or (5A)” in the definition of “cleared status certificate” and substituting the words “or (5)”;

(b)

by inserting, immediately after the definition of “Control Order”, the following definition:

“ “COVID‑19 naïve individual” means an individual who is not a recovered individual;”;

(c)

by inserting, immediately after the definition of “occupier”, the following definition:

“ “primary vaccination” means undergoing a vaccination after which the individual vaccinated is eligible to be granted under regulation 6 a certificate stating that he or she has a cleared status (general) for a definite period of at least 270 days;”; and

(d)

by inserting, immediately after the definition of “treating doctor”, the following definitions:

“ “Type S recovered individual” means a recovered individual because he or she tested positive for SARS‑CoV‑2 upon undergoing a test mentioned in paragraph (a)(iii) of the definition of “recovered individual”;

“Type T recovered individual” means a recovered individual because he or she tested positive for SARS‑CoV‑2 upon undergoing a test mentioned in paragraph (a)(i), (ii) or (iv) of the definition of “recovered individual”;”.

Amendment of regulation 6

3. Regulation 6 of the principal Regulations is amended by deleting paragraphs (3), (4), (5) and (5A) and substituting the following paragraphs:

“(3) Where the Director is satisfied that —

(a)	an individual is a recovered individual; and
(b)	the individual is vaccinated against a COVID‑19 infection by the administration of any approved vaccine by a recognised vaccination provider,

the Director may grant a certificate stating that the recovered individual has a cleared status (general) for a period as follows, whichever is applicable:

(c)	for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination;
(d)	for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination.

(4) In addition, where the Director is satisfied that an individual who is a COVID‑19 naïve individual is vaccinated against a COVID‑19 infection by the administration of any approved vaccine by a recognised vaccination provider, the Director may grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:

(a)

unless sub‑paragraph (b) applies —

(i)	for an indefinite period starting the day stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; or
(ii)	for a period that starts and ends as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination;

(b)

if the COVID‑19 naïve individual undergoes a primary vaccination before attaining 18 years of age, for a period that —

(i)	starts as stated in the First Schedule corresponding to the approved vaccine used in the vaccination and the nature of the individual’s vaccination; and
(ii)	ends at the expiry of 2 months after the individual attains 18 years of age or the end date stated in the First Schedule corresponding to the approved vaccine used in the individual’s primary vaccination, whichever date is later.

(5) Despite paragraph (2), (3) or (4), where an individual is diagnosed as having a COVID‑19 infection, after he or she underwent vaccination and is granted a certificate under paragraph (3) or (4), the Director or a recognised medical practitioner may, where satisfied that the individual is a recovered individual after that infection or any later infection, grant a certificate stating that the individual has a cleared status (general) for a period as follows, whichever is applicable:

(a)

if the recovered individual underwent only a primary vaccination or was granted a certificate under paragraph (4) stating that the individual has a cleared status (general) for a period of 120 days — for an indefinite period starting the date the recovered individual first tested positive for SARS‑CoV‑2 upon undergoing any of the following that led to the diagnosis of the individual having the last infection:

(i)	a polymerase chain reaction test;
(ii)	an antigen rapid test followed by a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection;
(iii)	an antigen rapid test on or after 6 January 2022 that is performed by or under the direction of the individual’s treating doctor in the course of providing medical treatment to the individual because the individual has acute respiratory symptoms;
(iv)	a serology test in Singapore that is not attributable to the administration of any vaccine against a COVID‑19 infection and without having tested positive for SARS‑CoV‑2 on any other occasion, but only if such individual was granted a certificate under paragraph (4);

(b)

if the recovered individual was granted a certificate under paragraph (3) for a period mentioned in paragraph (3)(d) — for a period that starts on a relevant date mentioned in sub‑paragraph (a) and ends at the expiry of 180 days (including that date) thereafter.”.

Amendment of regulation 8A

4. Regulation 8A of the principal Regulations is amended —

(a)

by inserting, immediately after the words “has a cleared status (general)” in paragraph (2), the words “other than for an indefinite period”;

(b)

by deleting the words “, (5) or (5A)” wherever they appear in paragraph (2) and substituting in each case the words “or (5)”; and

(c)

by inserting, immediately after paragraph (2), the following paragraph:

“(3) For the purposes of these Regulations, an individual who has a cleared status (general) for an indefinite period because he or she is granted a certificate under regulation 6(3), (4) or (5) does not have a cleared status (general) that is current after the cancellation of the certificate under regulation 6(6).”.

Deletion and substitution of First Schedule

5. The First Schedule to the principal Regulations is deleted and the following Schedule substituted therefor:

“FIRST SCHEDULE

Regulations 2(1) and (4), 6(3) and (4) and 7B(2)

Vaccination and approved vaccines

First column

Second column

Third column

Fourth column

Approved vaccine

Vaccination

Start

End

1.	Tozinameran (Pfizer‑BioNTech COVID‑19 vaccine or Comirnaty COVID‑19 vaccine)

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	Two doses of the approved vaccine opposite, administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the second dose is administered.

(5)	One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(6)	Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine where the doses are administered at such other intervals as may be allowed by the Director.

14th day after the second dose is administered in accordance with the second column.

The following day (including that day) after the day the second dose is administered:

(a)	120th day where the second dose is a defined approved vaccine;

(b)	270th day for any other approved vaccine.

(7)	Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)	Two doses of the approved vaccine opposite, followed by one dose of another approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)

One dose of the approved vaccine opposite, followed by 2 doses of another approved vaccine that is not a defined approved vaccine or a combination of approved vaccines none of which is a defined approved vaccine, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(10)	One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(13)	At least 3 doses one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the second and third doses.

(14)	Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses.

2.	Spikevax (Moderna COVID‑19 vaccine)

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	Two doses of the approved vaccine opposite, administered at least 24 days apart.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(5)	One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(6)	Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director.

14th day after the second dose is administered in accordance with the second column.

The following day (including that day) after the day the second dose is administered:

(a)	120th day where the second dose is a defined approved vaccine;

(b)	270th day for any other approved vaccine.

(7)	Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)	Two doses of the approved vaccine opposite followed by one dose of any other approved vaccine, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(10)	One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(13)	At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director.

The day the third dose is administered in accordance with the second column.

(14)	Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

3.	Covishield COVID‑19 vaccine or Vaxzevria (AstraZeneca COVID‑19 vaccine)

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	Two doses of the approved vaccine opposite, administered at least 24 days apart.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(5)	One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(6)	Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director.

14th day after the second dose is administered in accordance with the second column.

The following day (including that day) after the day the second dose is administered:

(a)	120th day where the second dose is a defined approved vaccine;

(b)	270th day for any other approved vaccine.

(7)	Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)	Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(10)	One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(13)	At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director.

The day the third dose is administered in accordance with the second column.

(14)	Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

4.	Johnson & Johnson’s (J&J) Janssen COVID‑19 vaccine

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	One dose of the approved vaccine opposite.

14th day after the dose is administered.

270th day (including that day) after the day the dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 86 days after the firstmentioned dose was administered.

The day the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(5)	At least 2 doses of approved vaccines, one of which is the approved vaccine opposite, and where the doses are administered at a shorter interval than as specified in paragraph (4) and allowed by the Director.

The day the second dose is administered in accordance with the second column.

270th day (including that day) after the day the first dose is administered plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the first and second doses.

5.	Sinopharm COVID‑19 vaccine

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

120th day (including that day) after the day the dose is administered.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

120th day (including that day) after the day the dose is administered.

(3)

Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(4)	Two doses of the approved vaccine opposite, or a combination of defined approved vaccines, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(5)

One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(6)

One dose of the approved vaccine opposite and a second dose of another approved vaccine that is not a defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(7)	Two doses of the approved vaccine opposite, administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(8)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(9)	Three doses of the defined approved vaccine opposite, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(10)	Two doses of the defined approved vaccine opposite followed by a third dose either of Sinovac‑Coronavac COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	One dose of the defined approved vaccine opposite, followed by a dose of Sinovac‑Coronavac COVID‑19 vaccine, then followed by a third dose of any approved vaccine, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(13)	Vaccination as described in paragraph (9) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(14)	Vaccination as described in paragraph (10), (11) or (12) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (13) or (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

270th day (including that day) after the start of the period in paragraph (9), (10), (11) or (12) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses.

6.	Sinovac‑Coronavac COVID‑19 vaccine

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

120th day (including that day) after the day the dose is administered.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

120th day (including that day) after the day the dose is administered.

(3)

Two doses of the approved vaccine opposite, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 13 days after the firstmentioned dose was administered.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(4)

One dose of the approved vaccine opposite and a dose of another defined approved vaccine, administered to a Type T recovered individual, the first dose of which is administered at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2 and the second dose at least 17 days after the firstmentioned dose was administered.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(5)	Two doses of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 13 days apart.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(6)	One dose of the approved vaccine opposite and one dose of another defined approved vaccine, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection, where the respective doses are each administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(7)

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)

14th day after the second dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)	Two doses of the approved vaccine opposite, administered at least 13 days apart.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(10)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(11)	Three doses of the defined approved vaccine opposite, where the first 2 doses are administered at least 13 days apart, and where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Two doses of the defined approved vaccine opposite administered at least 13 days apart, followed by a third dose either of Sinopharm COVID‑19 vaccine or another approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(13)	One dose of the defined approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, followed by a third dose of a defined approved vaccine, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(14)	One dose of the defined approved vaccine opposite, followed by a dose of Sinopharm COVID‑19 vaccine, followed by a third dose of any approved vaccine, where each dose is administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(15)	Vaccination as described in paragraph (11) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(16)	Vaccination as described in paragraph (12), (13) or (14) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(17)	At least 4 doses of approved vaccines, one of which is the approved vaccine opposite, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (15) or (16) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

270th day (including that day) after the start of the period in paragraph (11), (12), (13) or (14) (as the case may be) plus a period fixed by the Director, being not more than 85 days and corresponding to the actual interval between the third and fourth doses.

7.	Covaxin COVID‑19 vaccine

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	Two doses of the approved vaccine opposite, administered at least 24 days apart.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 24 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(5)	One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(6)	Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director.

14th day after the second dose is administered in accordance with the second column.

The following day (including that day) after the day the second dose is administered:

(a)	120th day where the second dose is a defined approved vaccine;

(b)	270th day for any other approved vaccine.

(7)	Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 24 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)	Two doses of the approved vaccine opposite administered at least 24 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(10)	One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(13)	At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director.

The day the third dose is administered in accordance with the second column.

(14)	Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

8.	COVOVAX COVID‑19 vaccine or Nuvaxovid (Novavax COVID‑19 vaccine)

(1)	One dose of the approved vaccine opposite, administered to a Type T recovered individual at least 28 days after the recovered individual first tested positive for SARS‑CoV‑2.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(2)	One dose of the approved vaccine opposite, administered to a Type S recovered individual after his or her recovery from the COVID‑19 infection.

14th day after the dose is administered in accordance with the second column.

Indefinite after the start of the period.

(3)	Two doses of the approved vaccine opposite, administered at least 17 days apart.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(4)	One dose of the approved vaccine opposite, followed by a dose of another approved vaccine that is not a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

270th day (including that day) after the day the second dose is administered.

(5)	One dose of the approved vaccine opposite, followed by a dose of a defined approved vaccine, administered at least 17 days after the firstmentioned dose is administered.

14th day after the second dose is administered in accordance with the second column.

120th day (including that day) after the day the second dose is administered.

(6)	Two doses of the approved vaccine opposite or one dose thereof in combination with a dose of another approved vaccine, where the doses are administered at such other intervals as may be allowed by the Director.

14th day after the second dose is administered in accordance with the second column.

The following day (including that day) after the day the second dose is administered:

(a)	120th day where the second dose is a defined approved vaccine;

(b)	270th day for any other approved vaccine.

(7)	Three doses of the approved vaccine opposite, where the first 2 doses are administered at least 17 days apart, and where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(8)	Two doses of the approved vaccine opposite administered at least 17 days apart, followed by one dose of another approved vaccine administered at least 86 days after the second dose is administered.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(9)

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(10)	One dose of the approved vaccine opposite, followed by 2 doses of any defined approved vaccine or combination of defined approved vaccines, where the respective doses are each administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(11)	Vaccination in accordance with paragraph (6) where the second dose is a defined approved vaccine, followed by another dose of any defined approved vaccine, where the second and third doses are administered at least 17 days apart.

The day the third dose is administered in accordance with the second column.

270th day (including that day) after the day the third dose is administered.

(12)	Vaccination in accordance with paragraph (6) where the second dose is an approved vaccine that is not a defined approved vaccine, followed by a third dose of any approved vaccine that is not a defined approved vaccine, where the second and third doses are administered at least 86 days apart.

The day the third dose is administered in accordance with the second column.

Indefinite after the start of the period.

(13)	At least 3 doses of approved vaccines, one of which is the approved vaccine opposite, and where the second and third doses are administered at a shorter interval than as specified in paragraph (7), (8), (9) or (12) and allowed by the Director.

The day the third dose is administered in accordance with the second column.

(14)	Vaccination in accordance with paragraph (10) followed by a fourth dose of any approved vaccine administered at least 86 days after the third dose is administered.

The day the fourth dose is administered in accordance with the second column.

Indefinite after the start of the period.

(15)	At least 4 doses where vaccination is in accordance with paragraph (10) for the first 3 doses and the fourth dose is any approved vaccine, and where the third and fourth doses are administered at a shorter interval than as specified in paragraph (14) and allowed by the Director.

The day the fourth dose is administered in accordance with the second column.

”.

[G.N. Nos. S 310/2021; S 324/2021; S 367/2021; S 396/2021; S 513/2021; S 542/2021; S 590/2021; S 620/2021; S 682/2021; S 768/2021; S 774/2021; S 863/2021; S 908/2021; S 991/2021; S 9/2022; S 49/2022; S 69/2022]

Made on 14 February 2022.

NG HOW YUE

Permanent Secretary
(Health Development),
Ministry of Health,
Singapore.

[AG/LEGIS/SL/137/2020/13 Vol. 1]

Search within Legislation